Managers / Q3 2021
Burrage Capital Management LLC
CIK 0001796461 · 314 COMMONWEALTH AVENUE, #4, BOSTON, MA, 02115 · 617-410-4770
Reported Value
$0
Q3 2021
Positions
1
Filings on Record
8
2019–present window
Filed
Nov 15, 2021
original filing
Summary
Compared with Q2 2021, the fund opened 1 new position and exited 22.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
vs Q2 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| 0 | NEW | +0 | 0 | +$0 | $0 |
| BCRXBIOCRYST PHARMACEUTICALS INC | SOLD OUT | −864.9K | 0 | −$14M | $0 |
| NTLAINTELLIA THERAPEUTICS INC | SOLD OUT | −63.6K | 0 | −$10M | $0 |
| EPIZYME INC | SOLD OUT | −836.8K | 0 | −$7M | $0 |
| ESSA PHARMA INC | SOLD OUT | −237.4K | 0 | −$7M | $0 |
| NEONEOGENOMICS INC | SOLD OUT | −147.9K | 0 | −$7M | $0 |
| MEI PHARMA INC | SOLD OUT | −2.33M | 0 | −$7M | $0 |
| CRNXCRINETICS PHARMACEUTICALS IN | SOLD OUT | −294.6K | 0 | −$6M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2021
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $0 | 1 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $100M | 22 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $123M | 27 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $131M | 25 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $127M | 27 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $143M | 26 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $102M | 31 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $149M | 29 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.